{"id":249916,"date":"2023-05-23T00:00:00","date_gmt":"2023-05-23T00:00:00","guid":{"rendered":"http:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidon0023-biopharma-myelodysplastic-syndromes-epidemiology-mature\/"},"modified":"2026-03-31T10:33:25","modified_gmt":"2026-03-31T10:33:25","slug":"epidon0023-biopharma-myelodysplastic-syndromes-epidemiology-mature-markets","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidon0023-biopharma-myelodysplastic-syndromes-epidemiology-mature-markets\/","title":{"rendered":"Myelodysplastic Syndromes &#8211; Epidemiology &#8211; Mature Markets"},"content":{"rendered":"<p>Clarivate Epidemiology\u2019s coverage of myelodysplastic syndromes (<abbr title=\"myelodysplastic syndromes\">MDS<\/abbr>) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of <abbr title=\"myelodysplastic syndromes\">MDS<\/abbr> for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Most patient populations are forecast over a period of 20 years for the major pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy.<\/p>\n<p>Clarivate Epidemiology\u2019s <abbr title=\"myelodysplastic syndromes\">MDS<\/abbr> forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li><!--[endif]-->In developing countries, what impact will economic growth and development have on the number of people diagnosed with <abbr title=\"myelodysplastic syndromes\">MDS<\/abbr> per year?<\/li>\n<li>How will improvements in survival change the number of people living with a diagnosis of <abbr title=\"myelodysplastic syndromes\">MDS<\/abbr>?<\/li>\n<li><!--[endif]-->Of all people diagnosed with <abbr title=\"myelodysplastic syndromes\">MDS<\/abbr>, how many in each country in the developed world are drug-treated?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"myelodysplastic syndromes\">MDS<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to <span class=\"abbreviation-guard\">MS <\/span>Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graph depicting the patient flow between or within different disease states for the major mature pharmaceutical markets. These patient-flow diagrams are provided at the regional level but may be requested for any specific country or forecast year.<\/p>\n<p>Clarivate Epidemiology provides at least 10 years of forecast data for the following <abbr title=\"myelodysplastic syndromes\">MDS<\/abbr> patient populations:<\/p>\n<ul class=\"round-bullets\">\n<li>Diagnosed incident cases of <abbr title=\"myelodysplastic syndromes\">MDS<\/abbr>.<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"myelodysplastic syndromes\">MDS<\/abbr>.<\/li>\n<li>Diagnosed incident cases of <abbr title=\"myelodysplastic syndromes\">MDS<\/abbr> by <abbr title=\"fms-like tyrosine kinase 3\">FLT3<\/abbr> status.<!--[if !supportLists]--><\/li>\n<li><!--[endif]-->Diagnosed incident cases of <abbr title=\"myelodysplastic syndromes\">MDS<\/abbr> by histology.<\/li>\n<li><!--[endif]-->Diagnosed prevalent cases of <abbr title=\"myelodysplastic syndromes\">MDS<\/abbr> by <abbr title=\"International Prognostic Scoring System\">IPSS<\/abbr> risk.<\/li>\n<li><!--[endif]-->Diagnosed prevalent cases of <abbr title=\"myelodysplastic syndromes\">MDS<\/abbr> by <abbr title=\"Revised International Prognostic Scoring System\">IPSS-R<\/abbr> risk.<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"myelodysplastic syndromes\">MDS<\/abbr> by histology.<\/li>\n<li>Diagnosed incident cases of <abbr title=\"myelodysplastic syndromes\">MDS<\/abbr> by <abbr title=\"fms-like tyrosine kinase 3\">FLT3<\/abbr>-mutation status.<\/li>\n<li>Drug-treated population(s).<\/li>\n<li>Diagnosed incident cases of <abbr title=\"myelodysplastic syndromes\">MDS<\/abbr> by\u00a0<abbr title=\"tumor protein p53\">TP53<\/abbr>-mutation status.<\/li>\n<\/ul>\n<p>\u2026 and more (details available on request).<\/p>\n<p>Note: Coverage may vary by country and region.<\/p>\n","protected":false},"template":"","class_list":["post-249916","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-hematological-malignancies","biopharma-therapy-areas-hematology","biopharma-therapy-areas-myelodysplastic-syndromes","biopharma-product-epidemiology","biopharma-date-975"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249916","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249916\/revisions"}],"predecessor-version":[{"id":281561,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249916\/revisions\/281561"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=249916"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}